In neurofibroma, SHP2 inhibition not only reduced tumor myeloid cells but also increased tumor T cells as a percentage of tumor immune cells, as in a GEM model of non–small-cell lung cancer (NSCLC) (Tang et al, 2022). The gene discussed is PTPN11; the disease is plexiform neurofibroma.